EyePoint Pharmaceuticals, Inc. (EYPT)

EyePoint Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	99.7	281.26	95.63	178.59	44.91
Short-Term Investments	271.21	49.79	48.93	32.97	-
Cash & Short-Term Investments	370.91	331.05	144.56	211.56	44.91
Cash Growth	12.04%	129.00%	-31.67%	371.08%	102.16%
Receivables	0.61	0.81	15.5	18.35	9.45
Inventory	2.31	3.91	2.89	3.62	5.34
Prepaid Expenses	8.08	8.03	9.08	4.22	3.42
Other Current Assets	1.41	1.01	0.78	-	-
Total Current Assets	383.31	344.8	172.81	237.75	63.12
Property, Plant & Equipment	29.18	10.23	7.4	2.73	3.24
Other Intangible Assets	-	-	-	22.75	25.21
Other Long-Term Assets	5.98	0.15	0.15	0.15	0.15
Total Assets	418.47	355.18	180.36	263.37	91.72
Accounts Payable	11.72	6.5	5.92	7.39	4.81
Accrued Expenses	17.96	16.76	15.34	11.45	7.34
Short-Term Debt	-	-	10.48	-	-
Current Portion of Leases	1.25	0.56	0.54	0.78	0.69
Current Unearned Revenue	17.78	38.59	1.21	1.07	0.95
Other Current Liabilities	0.34	0.84	1.05	2.97	1.11
Total Current Liabilities	49.05	63.26	34.54	23.66	14.89
Long-Term Debt	-	-	29.31	36.56	37.98
Long-Term Leases	21.86	4.91	5.98	1.9	2.4
Long-Term Unearned Revenue	10.85	20.69	13.56	14.56	15.62
Other Long-Term Liabilities	0.21	-	0.6	2.32	2.29
Total Liabilities	81.96	88.86	83.99	78.99	73.18
Common Stock	0.07	0.05	0.03	0.03	0.02
Additional Paid-In Capital	1,208	1,008	766.9	752.6	528.36
Retained Earnings	-873.02	-742.15	-671.35	-569.1	-510.68
Comprehensive Income & Other	1.03	0.86	0.79	0.84	0.84
Shareholders' Equity	336.5	266.32	96.37	184.38	18.54
Total Liabilities & Equity	418.47	355.18	180.36	263.37	91.72
Total Debt	23.11	5.47	46.31	39.24	41.07
Net Cash (Debt)	347.81	325.58	98.25	172.32	3.84
Net Cash Growth	6.83%	231.38%	-42.98%	4382.78%	-
Net Cash Per Share	6.18	8.37	2.63	5.99	0.30
Filing Date Shares Outstanding	68.73	49.83	34.3	34.04	28.74
Total Common Shares Outstanding	68.27	49.04	34.08	33.91	18.14
Working Capital	334.26	281.54	138.27	214.09	48.23
Book Value Per Share	4.93	5.43	2.83	5.44	1.02
Tangible Book Value	336.5	266.32	96.37	161.63	-6.67
Tangible Book Value Per Share	4.93	5.43	2.83	4.77	-0.37
Construction In Progress	1.51	3.73	-	-	-
Leasehold Improvements	4.13	1.01	1.01	0.26	0.26

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q